We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+20.37%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$1.29B
AUM Growth
+$421M
Cap. Flow
+$290M
Cap. Flow %
22.39%
Top 10 Hldgs %
49.01%
Holding
49
New
11
Increased
20
Reduced
8
Closed
8
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.5 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
DBVT icon
1
DBV Technologies
DBVT
$567M
$109M 8.41%
5,213,361
+4,216,536
+423% +$88.1M
2025 Q2
3 quarters
CGEM icon
2
Cullinan Therapeutics
CGEM
$577M
$109M 8.39%
7,648,268
– –
2021 Q1
20 quarters
AKTS icon
3
Aktis Oncology
AKTS
$901M
$86.5M 6.68%
+4,835,872
New +$93.9M
2026 Q1
0 quarters
LQDA icon
4
Liquidia
LQDA
$4.9B
$53M 4.1%
1,405,158
+4,289
+0.3% +$159K
2025 Q3
2 quarters
ALMS icon
5
Alumis
ALMS
$514M
$52.6M 4.06%
2,386,529
-15,463
-0.6% -$387K
2025 Q4
1 quarter
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.37B
$52.3M 4.04%
1,660,696
+5,440
+0.3% +$157K
2024 Q1
8 quarters
RVMD icon
7
Revolution Medicines
RVMD
$34.9B
$49.3M 3.81%
506,776
+1,104
+0.2% +$111K
2021 Q3
18 quarters
AGIO icon
8
Agios Pharmaceuticals
AGIO
$1.65B
$44.2M 3.41%
1,306,261
+2,888
+0.2% +$81.9K
2025 Q4
1 quarter
CORT icon
9
Corcept Therapeutics
CORT
$6.88B
$39.7M 3.07%
+985,700
New +$36.9M
2026 Q1
0 quarters
TRVI icon
10
Trevi Therapeutics
TRVI
$1.9B
$39.4M 3.04%
3,298,430
+11,343
+0.3% +$127K
2024 Q1
8 quarters
DNTH icon
11
Dianthus Therapeutics
DNTH
$4.76B
$35.6M 2.75%
+423,982
New +$24.6M
2026 Q1
0 quarters
XENE icon
12
Xenon Pharmaceuticals
XENE
$3.64B
$34.2M 2.64%
588,706
+103,086
+21% +$4.75M
2024 Q3
6 quarters
MLTX icon
13
MoonLake Immunotherapeutics
MLTX
$942M
$33.8M 2.61%
+1,811,082
New +$30M
2026 Q1
0 quarters
TVTX icon
14
Travere Therapeutics
TVTX
$4.51B
$33.7M 2.6%
+1,133,365
New +$33.9M
2026 Q1
0 quarters
EVMN icon
15
Evommune
EVMN
$291M
$33.5M 2.58%
1,455,863
+1,342,841
+1,188% +$30.4M
2025 Q4
1 quarter
CYTK icon
16
Cytokinetics
CYTK
$7.07B
$33M 2.55%
+500,000
New +$31.8M
2026 Q1
0 quarters
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$785M
$31.3M 2.42%
1,340,733
+3,031
+0.2% +$65.9K
2025 Q3
2 quarters
CNTX icon
18
Context Therapeutics
CNTX
$14.7M
$28M 2.16%
10,679,391
– –
2024 Q4
5 quarters
FBRX icon
19
DELISTED
Forte Biosciences
FBRX
$25.9M 2%
+1,000,682
New +$28.8M
2026 Q1
0 quarters
PVLA icon
20
Palvella Therapeutics
PVLA
$2.09B
$25.7M 1.99%
206,404
+659
+0.3% +$68.7K
2025 Q3
2 quarters
DYN icon
21
Dyne Therapeutics
DYN
$2.9B
$25.5M 1.97%
1,408,152
+2,764
+0.2% +$47.7K
2025 Q2
3 quarters
STOK icon
22
Stoke Therapeutics
STOK
$1.75B
$25M 1.93%
767,038
-3,251
-0.4% -$107K
2024 Q3
6 quarters
CRVS icon
23
Corvus Pharmaceuticals
CRVS
$816M
$24.5M 1.89%
1,674,875
-1,068,796
-39% -$17.1M
2025 Q4
1 quarter
RLAY icon
24
Relay Therapeutics
RLAY
$3.56B
$23.5M 1.81%
2,359,586
+127,135
+6% +$1.14M
2023 Q1
12 quarters
TARS icon
25
Tarsus Pharmaceuticals
TARS
$3.6B
$23.1M 1.79%
329,750
+881
+0.3% +$61.6K
2025 Q2
3 quarters

Similar funds

MPM BioImpact's Q1 2026 Portfolio in Review

As of Q1 2026, MPM BioImpact held 49 positions worth $1.29B, up 48% from $874M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

MPM BioImpact deployed $290M of net new capital in Q1 2026, opening 11 new positions and adding to 20 existing holdings. Its largest new stake was Aktis Oncology: 4,835,872 shares worth $86.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Corvus Pharmaceuticals, an estimated $17.1M trimmed.

  • MPM BioImpact's largest Q1 2026 buy was Aktis Oncology: 4,835,872 shares worth $86.5M.
  • MPM BioImpact added most to DBV Technologies in Q1 2026, an estimated $88.1M increase.
  • MPM BioImpact's biggest Q1 2026 reduction was Corvus Pharmaceuticals, cutting an estimated $17.1M.
  • MPM BioImpact fully exited Madrigal Pharmaceuticals in Q1 2026, selling an estimated $56.4M.
  • MPM BioImpact's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2026.
  • MPM BioImpact opened 11 new positions and closed 8 in Q1 2026.
  • MPM BioImpact's portfolio value rose 48% quarter-over-quarter to $1.29B.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.